Innovations in Oncology Diagnostics: Genetic Research and Liquid Biopsy as Tools of Personalised Medicine

Niyazbekova L. Marku E. Petkov P. Karimova N. Ulmasov F.
December 2025 Asian Pacific Organization for Cancer Prevention

Asian Pacific Journal of Cancer Prevention
2025 #26 Issue 12 4549 - 4561 pp.

Objective: The aim of this study was to analyze contemporary approaches to cancer diagnosis and treatment using liquid biopsy, with a particular focus on the efficacy of oncogenic biomarker detection in various biological fluids. Materials and Methods: This study examined scientific literature from the last five years on the use of liquid biopsy in oncology, focusing on tumour marker detection in blood, plasma, saliva, and urine, along with their analytical significance and clinical implications. Results: Tumour-derived circulating nucleic acids, circulating tumour cells, and secretory vesicles isolated from biological fluids were shown to be highly informative. These enabled the detection of mutations in key oncogenic markers (AR, KRAS, EGFR, PIK3CA, PTEN, P53), quantification of regulatory RNAs (BCAR4, UCA1, H19, miR-21, miR-146a-5p, miR-181a), and assessment of translational levels of proteins such as Cfh, Muc1, Bst2, Er, and Ccne1. Transcriptomic analysis provided insights into T-lymphocyte activity, tumour resistance to gefitinib and tyrosine kinase inhibitors, and the suppression of tumour progression. The expression of proteoglycans isolated from exosomes was identified as a marker of early-stage pancreatic cancer. The titre of CTCs enabled the prediction of recurrence in 64% of patients with lung carcinoma and 100% of post-surgical cases of colorectal cancer, facilitating hormone therapy adjustments in prostate cancer patients. Mutations in the EGFR gene, amplified from persistent deoxyribonucleic acid, were used to adjust chemotherapy regimens throughout the course of treatment. Conclusion: The analysis of material obtained from the biological fluids of oncology patients enabled disease prognosis, risk assessment of progression, and the determination of optimal approaches to personalised therapy, ultimately improving treatment efficacy. The collected data may serve as a foundation for clinically valuable laboratory studies and practical research.

epigenetic changes , exosomes , mutation , sequencing , tumour markers

Text of the article Перейти на текст статьи

Department of Pathological Physiology named after Professor A.N. Nurmukhambetov, Kazakh State Medical University named after S.D. Asfendiyarov, Almaty, Kazakhstan
Department of Pre-Clinical Studies, University of Medicine, Tirana, Albania
Alexandrovska Hospital, Sofia, Bulgaria
Department of Clinical Disciplines No. 2, Osh State, University Osh, Kyrgyzstan
Department of Oncology, Samarkand State Medical University, Samarkand, Uzbekistan

Department of Pathological Physiology named after Professor A.N. Nurmukhambetov
Department of Pre-Clinical Studies
Alexandrovska Hospital
Department of Clinical Disciplines No. 2
Department of Oncology

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026